ZA201901035B - Assay for determining potential to self-association of a protein using concentration-dependent self-interaction nanoparticle spectroscopy - Google Patents
Assay for determining potential to self-association of a protein using concentration-dependent self-interaction nanoparticle spectroscopyInfo
- Publication number
- ZA201901035B ZA201901035B ZA2019/01035A ZA201901035A ZA201901035B ZA 201901035 B ZA201901035 B ZA 201901035B ZA 2019/01035 A ZA2019/01035 A ZA 2019/01035A ZA 201901035 A ZA201901035 A ZA 201901035A ZA 201901035 B ZA201901035 B ZA 201901035B
- Authority
- ZA
- South Africa
- Prior art keywords
- self
- protein
- concentration
- assay
- association
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
- G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
- G01N21/77—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/585—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
- G01N33/587—Nanoparticles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
- G01N2021/258—Surface plasmon spectroscopy, e.g. micro- or nanoparticles in suspension
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nanotechnology (AREA)
- Plasma & Fusion (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicinal Preparation (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Materials By Optical Means (AREA)
- Analysing Materials By The Use Of Radiation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662376788P | 2016-08-18 | 2016-08-18 | |
| PCT/US2017/047630 WO2018035470A1 (en) | 2016-08-18 | 2017-08-18 | Assay for determining potential to self-association of a protein using concentration-dependent self-interaction nanoparticle spectroscopy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201901035B true ZA201901035B (en) | 2024-06-26 |
Family
ID=59746357
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2019/01035A ZA201901035B (en) | 2016-08-18 | 2019-02-18 | Assay for determining potential to self-association of a protein using concentration-dependent self-interaction nanoparticle spectroscopy |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US11428695B2 (enExample) |
| EP (2) | EP3500856B1 (enExample) |
| JP (3) | JP6959327B2 (enExample) |
| KR (3) | KR102717462B1 (enExample) |
| CN (2) | CN115468919A (enExample) |
| AU (2) | AU2017313150B2 (enExample) |
| BR (1) | BR112019003175A2 (enExample) |
| CA (3) | CA3254461A1 (enExample) |
| DK (2) | DK3500856T3 (enExample) |
| EA (1) | EA201990316A1 (enExample) |
| ES (2) | ES2974961T3 (enExample) |
| FI (1) | FI3761035T3 (enExample) |
| HU (2) | HUE052805T2 (enExample) |
| IL (2) | IL264640B2 (enExample) |
| MX (2) | MX2019001930A (enExample) |
| PL (2) | PL3500856T3 (enExample) |
| SG (1) | SG11201900895QA (enExample) |
| WO (1) | WO2018035470A1 (enExample) |
| ZA (1) | ZA201901035B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE052805T2 (hu) | 2016-08-18 | 2021-05-28 | Regeneron Pharma | Fehérje önasszociációs képességének meghatározására szolgáló assay koncentrációfüggõ öninterakciós nanorészecske-spektroszkópia segítségével |
| PT4364724T (pt) | 2018-05-10 | 2025-12-16 | Regeneron Pharma | Formulações contendo uma proteína de fusão do recetor do vegf de concentração elevada |
| CN113588582B (zh) * | 2020-04-30 | 2024-05-14 | 上海药明生物技术有限公司 | 蛋白质样品浓度测定方式选择法及测定方法 |
| WO2023095154A1 (en) * | 2021-11-24 | 2023-06-01 | Sensoville Biotech Pvt Ltd | Method for determining changes in a protein's structure |
| WO2023141319A1 (en) * | 2022-01-24 | 2023-07-27 | Amgen Inc. | Methods for detecting antibody self-association |
| CN119832975A (zh) * | 2024-12-24 | 2025-04-15 | 上海药明生物技术有限公司 | 一种蛋白质共处方制剂的稳定性预测方法 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US771997A (en) | 1903-11-21 | 1904-10-11 | Alfred Palm | Lathe attachment. |
| US4254102A (en) * | 1975-09-08 | 1981-03-03 | Plough, Inc. | Substantive PABA compositions |
| US4080264A (en) | 1976-03-01 | 1978-03-21 | Massachusetts Institute Of Technology | Immunoassay by light scattering spectroscopy |
| US6927044B2 (en) | 1998-09-25 | 2005-08-09 | Regeneron Pharmaceuticals, Inc. | IL-1 receptor based cytokine traps |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| US20050214356A1 (en) * | 2004-03-24 | 2005-09-29 | Joyce Timothy H | Self assembling activation agents targeted using active drug release |
| US20050221507A1 (en) * | 2004-03-30 | 2005-10-06 | Intel Corporation | Method to detect molecular binding by surface-enhanced Raman spectroscopy |
| US7514938B2 (en) | 2004-05-11 | 2009-04-07 | Board Of Regents Of The University And College System Of Nevada, On Behalf Of The University Of Nevada, Reno | Dielectric relaxation spectroscopy apparatus and methods of use |
| TW200621282A (en) | 2004-08-13 | 2006-07-01 | Wyeth Corp | Stabilizing formulations |
| ES2352509T3 (es) * | 2005-05-02 | 2011-02-21 | Baseclick Gmbh | Nuevas estrategias de marcaje para la detección sensible de analitos. |
| US20070291265A1 (en) | 2006-04-13 | 2007-12-20 | Mississippi State University | Optical apparatus for simultaneously measuring the scattering and concentration of signals of macromolecules in a flow cell |
| JP2010506839A (ja) | 2006-10-12 | 2010-03-04 | ワイス エルエルシー | 乳光の低減を伴う方法および組成物 |
| GB0621050D0 (en) * | 2006-10-23 | 2006-11-29 | Univ Strathclyde | Functionalised polymers for labelling metal surfaces |
| EP2150617B1 (en) | 2007-06-04 | 2014-10-22 | Regeneron Pharmaceuticals, Inc. | Enhanced expression and stability regions |
| WO2009039502A1 (en) * | 2007-09-21 | 2009-03-26 | Cytimmune Sciences, Inc. | Nanotherapeutic colloidal metal compositions and methods |
| US20110305765A1 (en) | 2008-11-21 | 2011-12-15 | Board Of Regents, The University Of Texas System | Preparation and methodology of silk fibroin nanoparticles |
| US20140024024A1 (en) * | 2012-07-17 | 2014-01-23 | General Electric Company | Methods of detecting dna, rna and protein in biological samples |
| JP6099108B2 (ja) | 2013-05-30 | 2017-03-29 | 公立大学法人大阪府立大学 | 被検出物質の検出装置および方法 |
| IL312865B2 (en) * | 2013-09-11 | 2025-06-01 | Eagle Biologics Inc | Liquid protein formulations containing viscosity-lowering agents |
| EP2902503A1 (en) * | 2014-01-31 | 2015-08-05 | Fundación Imdea Nanociencia | Functionalized metal nanoparticles and uses thereof for detecting nucleic acids |
| US20160074515A1 (en) * | 2014-06-20 | 2016-03-17 | Reform Biologics, Llc | Viscosity-reducing excipient compounds for protein formulations |
| CN104062287B (zh) | 2014-07-01 | 2017-08-08 | 福建工程学院 | 一种基于纳米金催化的化学发光分析检测铁蛋白的方法 |
| MA40861A (fr) * | 2014-10-31 | 2017-09-05 | Biogen Ma Inc | Anticorps anti-glycoprotéines iib/iiia |
| WO2016115475A1 (en) * | 2015-01-18 | 2016-07-21 | Biogen Ma Inc. | Anti-cd40 antibody formulations |
| HUE052805T2 (hu) | 2016-08-18 | 2021-05-28 | Regeneron Pharma | Fehérje önasszociációs képességének meghatározására szolgáló assay koncentrációfüggõ öninterakciós nanorészecske-spektroszkópia segítségével |
-
2017
- 2017-08-18 HU HUE17761159A patent/HUE052805T2/hu unknown
- 2017-08-18 WO PCT/US2017/047630 patent/WO2018035470A1/en not_active Ceased
- 2017-08-18 CA CA3254461A patent/CA3254461A1/en active Pending
- 2017-08-18 FI FIEP20191942.0T patent/FI3761035T3/fi active
- 2017-08-18 DK DK17761159.7T patent/DK3500856T3/da active
- 2017-08-18 ES ES20191942T patent/ES2974961T3/es active Active
- 2017-08-18 SG SG11201900895QA patent/SG11201900895QA/en unknown
- 2017-08-18 DK DK20191942.0T patent/DK3761035T3/da active
- 2017-08-18 EP EP17761159.7A patent/EP3500856B1/en active Active
- 2017-08-18 CN CN202211108451.8A patent/CN115468919A/zh active Pending
- 2017-08-18 KR KR1020237016537A patent/KR102717462B1/ko active Active
- 2017-08-18 EA EA201990316A patent/EA201990316A1/ru unknown
- 2017-08-18 CN CN201780050825.6A patent/CN109661577B/zh active Active
- 2017-08-18 KR KR1020197006376A patent/KR102441221B1/ko active Active
- 2017-08-18 HU HUE20191942A patent/HUE066064T2/hu unknown
- 2017-08-18 CA CA3254460A patent/CA3254460A1/en active Pending
- 2017-08-18 JP JP2019508809A patent/JP6959327B2/ja active Active
- 2017-08-18 ES ES17761159T patent/ES2837093T3/es active Active
- 2017-08-18 US US16/326,238 patent/US11428695B2/en active Active
- 2017-08-18 PL PL17761159T patent/PL3500856T3/pl unknown
- 2017-08-18 PL PL20191942.0T patent/PL3761035T3/pl unknown
- 2017-08-18 EP EP20191942.0A patent/EP3761035B1/en active Active
- 2017-08-18 CA CA3032361A patent/CA3032361C/en active Active
- 2017-08-18 MX MX2019001930A patent/MX2019001930A/es unknown
- 2017-08-18 KR KR1020227030436A patent/KR102534506B1/ko active Active
- 2017-08-18 AU AU2017313150A patent/AU2017313150B2/en active Active
- 2017-08-18 BR BR112019003175-8A patent/BR112019003175A2/pt active Search and Examination
- 2017-08-18 IL IL264640A patent/IL264640B2/en unknown
- 2017-08-18 IL IL307435A patent/IL307435A/en unknown
-
2019
- 2019-02-15 MX MX2023013583A patent/MX2023013583A/es unknown
- 2019-02-18 ZA ZA2019/01035A patent/ZA201901035B/en unknown
-
2021
- 2021-10-07 JP JP2021165510A patent/JP7321227B2/ja active Active
-
2022
- 2022-07-20 US US17/868,983 patent/US11988668B2/en active Active
-
2023
- 2023-07-25 JP JP2023120438A patent/JP2023139189A/ja active Pending
- 2023-12-04 AU AU2023274236A patent/AU2023274236A1/en active Pending
-
2024
- 2024-04-16 US US18/637,055 patent/US20240280582A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201901035B (en) | Assay for determining potential to self-association of a protein using concentration-dependent self-interaction nanoparticle spectroscopy | |
| CY1123642T1 (el) | Αντισωματα enanti-pd-1 | |
| CY1125392T1 (el) | Συνθεσεις και μεθοδοι γλυζυλιωσης πρωτεϊνων | |
| BR112015024553A2 (pt) | anticorpo multiespecífico, anticorpo isolado, ácido nucleico isolado, célula hospedeira, método de produção de anticorpo, imunoconjugado, formulação farmacêutica, uso de anticorpo e método de tratamento de indivíduos com distúrbio | |
| GEP20237513B (en) | Improved methods for enhancing antibody productivity in mammalian cell culture and minimizing aggregation during downstream, formulation processes and stable antibody formulations obtained thereof | |
| CY1125697T1 (el) | Σταθερες, υδατικες φαρμακοτεχνικες μορφες αντισωματων | |
| WO2014141152A3 (en) | Low concentration antibody formulations | |
| BR112019005328A2 (pt) | composição farmacêutica líquida | |
| GB2569252A (en) | Methods of combining the detection of biomolecules into a single assay using fluorescent in situ sequencing | |
| EA201891435A1 (ru) | Гуманизированные моноклональные антитела, моноклональные антитела мыши или химерные моноклональные антитела против cd47 | |
| EA201892616A1 (ru) | Антитела к pd1 и lag3 для лечения злокачественного новообразования | |
| EA201790877A1 (ru) | Подобный йогурту высокобелковый продукт на основе белка молочной сыворотки, ингредиент, подходящий для его получения, а также способ получения | |
| EA201690651A1 (ru) | Содержащие cmp высокобелковые композиции денатурированного сывороточного белка, содержащие их продукты и их применения | |
| BR112016014022A2 (pt) | anticorpos anti-cd3, ácido nucleico isolado, vetor, célula hospedeira, método de produção do anticorpo anti-cd3, imunoconjugado, composição, uso do anticorpo anti-cd3, métodos de tratamento, métodos de intensificação da função imune e kit | |
| CL2016002004A1 (es) | Anticuerpos anti-jagged1 y métodos de uso | |
| EA201591131A1 (ru) | Днк-конструкции антитела и способ их применения | |
| AR091098A1 (es) | ANTICUERPOS E INMUNOCONJUGADOS CONTRA Ly6E Y METODOS DE USO | |
| BR112014010222A8 (pt) | formulação de enzima líquida e processo para sua preparação | |
| AR088322A1 (es) | Anticuerpos anti-htra1 y metodos de uso | |
| EA201791424A1 (ru) | Получение белка | |
| BR112016014756A8 (pt) | formulação de selante compreendendo fibrinogênio e zimogênios, seu método de fabricação, recipiente e uso | |
| BR112017016897A2 (pt) | cepas fúngicas e métodos de uso | |
| CL2018002548A1 (es) | Regulación del metabolismo de ornitina para aumentar el contenido de glicoformas ricas en manosa de proteínas recombinantes.(divisional solicitud 201601786) | |
| MA47550A1 (fr) | Systèmes et procédés de préparation de boissons contenant de l'éthanol | |
| Khoshnava et al. | Obstacles and drivers in steering IBS towards green and sustainability |